Astria Therapeutics, Inc.
astriatx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Nov 12, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Feb 17, 2026.
10-Q for Q3 FY2025, filed Nov 12, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops antibody drug candidates for people with hereditary angioedema and atopic dermatitis.
10-K for FY2024, filed Mar 11, 2025We are a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and…View ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2025, filed Nov 12, 2025
−$31.6MView ↗
- ▲ +29% (Loss)
- vs −$24.5M in Q3 FY2024
-
Jan 23, 2026
BioCryst completed its acquisition of Astria
Astria became a wholly owned BioCryst subsidiary and requested Nasdaq delisting.
Sources
8-K, filed Jan 23, 2026
On the Closing Date, Astria and BioCryst completed the transactions contemplated by the Agreement and Plan of Merger, dated as of October…View ↗
-
Aug 6, 2025
Licensed navenibart rights in Japan to Kaken
The deal includes an upfront payment, potential sales milestones, royalties and partial development-cost reimbursement.
Sources
8-K, filed Aug 6, 2025
On August 6, 2025, Astria Therapeutics, Inc. (the “Company”) entered into a license agreement (the “License Agreement”) with Kaken…View ↗
Who Did They Compete With?
Competes with CSL Behring, Takeda, Pharming, BioCryst, Ionis Pharmaceuticals, Pharvaris, KalVista Pharmaceuticals, Intellia Therapeutics, ADARx Pharmaceuticals, Argo Biopharmaceutical, Ractigen Therapeutics, Amgen, Sanofi, Inmagene, Apogee, and AbCellera
10-K for FY2024, filed Mar 11, 2025In the United States, the FDA has approved four therapies for on-demand treatment of HAE: BERINERT, FIRAZYR, KALBITOR and RUCONEST. For…View ↗
Loading...
